The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Robin L. Jones on Eribulin Versus Dacarbazine in Patients With Leiomyosarcoma and Adipocytic Sarcoma

Robin L. Jones, BSc, MB, MRCP, MD
Published Online: 7:26 PM, Thu November 5, 2015

Robin L. Jones, BSc, MB, MRCP, MD, Consultant Oncologist, Royal Marsden Hospital, London, England, discusses results and takeaways from a phase III trial presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.

This randomized phase III trial analyzed patients with unresectable metastatic liposarcoma or leiomyosarcoma who had previously received at least two lines of chemotherapy. The primary endpoint was overall survival (OS).

In the trial, eribulin demonstrated significant benefit for patients: OS was 13.5 months compared with 11.5 months with dacarbazine.

Jones points out that this trial is significant because OS benefit is seldom seen soft tissue sarcoma studies.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.